PureTech's Deupirfenidone Aims to Redefine IPF Treatment Standards
Event summary
- PureTech Health will present data on deupirfenidone (LYT-100) at the ATS International Conference from May 15-20, 2026.
- The SURPASS-IPF Phase 3 trial is designed as the first head-to-head superiority study comparing deupirfenidone to pirfenidone in IPF.
- Deupirfenidone demonstrated potential to stabilize lung function decline in the Phase 2b ELEVATE IPF trial.
- Celea Therapeutics, a PureTech subsidiary, is advancing the program with a strategy to challenge existing IPF treatment paradigms.
The big picture
PureTech's focus on deupirfenidone reflects a strategic push to address the unmet need for more effective IPF treatments. The head-to-head trial design positions the program to potentially set a new standard of care, challenging the limitations of current antifibrotic therapies. This aligns with broader industry trends toward more differentiated and efficacious treatments for rare, progressive diseases.
What we're watching
- Clinical Superiority
- Whether deupirfenidone can demonstrate clear superiority over existing IPF treatments in the Phase 3 trial.
- Regulatory Pathway
- The pace at which PureTech advances deupirfenidone through regulatory approvals following Phase 3 data.
- Market Adoption
- How the potential efficacy and tolerability profile of deupirfenidone could drive adoption in the IPF treatment landscape.
Related topics